Pancreatic Cancer – Epidemiology Forecast to 2029

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Pancreatic cancer (International Statistical Classification of Diseases and Related Health Problems, 10th Revision [ICD-10] code = C25) is the seventh leading cause of cancer deaths worldwide. Pancreatic cancer occurs when cells in the pancreas develop mutations in their DNA and grow uncontrollably. These accumulating cells form a tumor. Untreated pancreatic cancer spreads to nearby organs and blood vessels. PDAC or pancreatic exocrine cancer is the most common type of pancreatic cancer and begins in the cells that line the ducts of the pancreas. PDAC is an aggressive form of pancreatic cancer where approximately 60–80% of patients already have distant metastasis at presentation.

GlobalData epidemiologists used age- and sex-specific diagnosed incidence and prevalence rates to forecast the diagnosed incident and prevalent cases, considering the significant relationship between age and incidence. GlobalData epidemiologists applied country-specific incidence rates of pancreatic cancer, wherever available, to each country’s population to obtain the number of estimated diagnosed incident cases.

The following data describes epidemiology of PDAC cases. In 2019, the 8MM had 178,128 diagnosed incident cases of PDAC. This is expected to increase to 224,769 diagnosed incident cases by 2029, at an Annual Growth Rate (AGR) of 2.62%. This increase is partly attributed to the moderately rising trend in incidence in the 8MM, combined with underlying demographic changes in the respective markets. In the 8MM, the five-year diagnosed prevalent cases of PDAC will increase from 113,292 cases in 2019 to 140,914 cases in 2029, at an AGR of 2.44%. The early diagnosis and development of more effective therapies, particularly for elderly patients, would improve survival from PDAC.

Scope

Pancreatic Cancer Epidemiology Report and Model provide an overview of the risk factors and global trends of pancreatic ductal adenocarcinoma (PDAC) in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Urban China).

This report also includes a 10-year epidemiological forecast for the following segmentations across the 8MM: diagnosed incident cases of pancreatic cancer and PDAC; PDAC segmented by sex and age (18–29 years, 30–39 years, 40–49 years, 50–59 years, 60–69 years, 70–79 years, and 80 years and older); diagnosed five–year prevalent cases PDAC; diagnosed incident cases of PDAC by cancer staging; and diagnosed incident cases of PDAC by biomarkers.

The Pancreatic Cancer Epidemiology Report and Model were written and developed by Masters- and PhD-level epidemiologists.

• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

• The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The PDAC Epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global pancreatic cancer and PDAC market.

Quantify patient populations in the global PDAC market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the PDAC cancer stages that present the best opportunities for PDAC therapeutics in each of the markets covered.

Understand magnitude of PDAC market by biomarkers.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Pancreatic Cancer: Executive Summary

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods

3.4.3 Diagnosed Incident Cases of Pancreatic Cancer and PDAC

3.4.4 Diagnosed Incident Cases of PDAC by Stages

3.4.5 Diagnosed Incident Cases of PDAC by Familial PDAC by Germline Mutation

3.4.6 Diagnosed Incident Cases of PDAC by KRAS and NTRK Gene Fusion Mutation

3.4.7 Diagnosed Incident Cases of PDAC by PD-L1 Expression

3.4.8 Five-Year Diagnosed Prevalent Cases of PDAC

3.5 Epidemiological Forecast for Pancreatic Cancer, 2019–2029

3.5.1 Diagnosed Incident Cases of Pancreatic Cancer

3.5.2 Diagnosed Incident Cases of PDAC

3.5.3 Sex-Specific Diagnosed Incident Cases of PDAC

3.5.4 Age-Specific Diagnosed Incident Cases of PDAC

3.5.5 Diagnosed Incident Cases of PDAC by Stage at Diagnosis

3.5.6 Diagnosed Incident Cases of Familial PDAC by Germline Mutations

3.5.7 Diagnosed Incident Cases of PDAC by KRAS and NTRK Gene Mutations

3.5.8 Diagnosed Incident Cases of PDAC by PD-L1 Expression

3.5.9 Five-Year Diagnosed Prevalent Cases of PDAC

3.6 Discussion

3.6.1 Epidemiological Forecast Insight

3.6.2 COVID-19 Impact

3.6.3 Limitations of the Analysis

3.6.4 Strengths of the Analysis

4 Appendix

4.1 Bibliography

4.2 About the Authors

4.2.1 Epidemiologist

4.2.2 Reviewers

4.2.3 Global Director of Therapy Analysis and Epidemiology

4.2.4 Global Head and EVP of Healthcare Operations and Strategy

4.3 About GlobalData

4.4 Contact Us

4.5 Disclaimer

Table

Table 1: Summary of Newly Added Data Types and Countries

Table 2: Summary of Updated Data Types

Table 3: Risk Factors and Comorbidities for PDAC

Figures

Figure 1: 8MM, Diagnosed Incident Cases of PDAC, Both Sexes, Ages ≥18 Years, N, 2019 and 2029

Figure 2: 8MM, Diagnosed Incidence of PDAC, Men, Ages ≥18 Years, 2009–2029, Cases Per 100,000 Population

Figure 3: 8MM, Diagnosed Incidence of PDAC, Women, Ages ≥18 Years, 2009–2029, Cases Per 100,000 Population

Figure 4: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of Pancreatic Cancer and PDAC

Figure 5: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of PDAC by Stage at Diagnosis

Figure 6: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Familial PDAC by Germline Mutation

Figure 7: 8MM, Sources Used to Forecast of PDAC by KRAS and NTRK Gene Fusion Mutation

Figure 8: 8MM, Sources Used to Forecast the PD-L1 Expression of PDAC

Figure 9: 8MM, Sources Used to Forecast Five-Year Diagnosed Prevalent Cases of PDAC

Figure 10: 8MM, Diagnosed Incident Cases of Pancreatic Cancer, Both Sexes, Ages ≥18 Years, N, 2019

Figure 11: 8MM, Diagnosed Incident Cases of PDAC, Both Sexes, Ages ≥18 Years, N, 2019

Figure 12: 8MM, Diagnosed Incident Cases of PDAC, by Sex, Ages ≥18 Years, N, 2019

Figure 13: 8MM, Diagnosed Incident Cases of PDAC by Age, Both Sexes, N, 2019

Figure 14: 8MM, Diagnosed Incident Cases of PDAC by Stage at Diagnosis, Ages ≥18 Years, Both Sexes, N, 2019

Figure 15: 8MM, Diagnosed Incident Cases of Familial PDAC by Germline Mutations, Ages ≥18 Years, Both Sexes, N, 2019

Figure 16: 8MM, Diagnosed Incident Cases of PDAC by KRAS and NTRK Gene Fusion Mutations, Ages ≥18 Years, Both Sexes, N, 2019

Figure 17: 8MM, Diagnosed Incident Cases of PDAC by PD-L1 Expression, Ages ≥18 Years, Both Sexes, N, 2019

Figure 18: 8MM, Five-Year Diagnosed Prevalent Cases of PDAC, Ages ≥18 Years, Both Sexes, N, 2019

Frequently asked questions

Pancreatic Cancer – Epidemiology Forecast to 2029 thematic reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Pancreatic Cancer – Epidemiology Forecast to 2029 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Pancreatic Cancer – Epidemiology Forecast to 2029 in real time.

  • Access a live Pancreatic Cancer – Epidemiology Forecast to 2029 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.